Teligent Company Profile (NASDAQ:TLGT)

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

Teligent, Inc. (NASDAQ:TLGT) released its earnings results on Tuesday, August, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.04. The business earned $18.40 million during the quarter, compared to analyst estimates of $20.11 million. Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $0.02 EPS. View Teligent's Earnings History.

3 brokers have issued 12 month price targets for Teligent's stock. Their forecasts range from $8.00 to $11.00. On average, they expect Teligent's stock price to reach $9.33 in the next year. View Analyst Ratings for Teligent.

Here are some recent quotes from research analysts about Teligent stock:

• 1. Canaccord Genuity analysts commented, "We’re confident that the company’s revised expectations are achievable and delays at the agency will resolve in short order. We continue to view Teligent as a uniquely positioned generic company poised for meaningful growth over the next several years. We maintain our BUY rating and $11 price target on TLGT shares. Light revenue due to lidocaine ointment and Zantac; lidocaine solution a surprising star in the report. Teligent’s 2Q/17 revenue was $18.4 mm compared to our $19mm estimate and $20.3 mm consensus. In our post-launch thoughts, we believed investors were expecting a light quarter and potential downward revision to 2H/17 expectations. Adjusted loss per share was ($0.01) compared to our EPS estimate of +$0.01 and consensus of +$0.02. Teligent saw incremental competition and double-digit price erosion on lidocaine ointment and a return of a competitor on Zantac injection coupled with lower-than-expected Zantac utilization rates due to recent inventory shortages that changed physician use patterns." (8/8/2017)
• 2. According to Zacks Investment Research, "Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. " (7/6/2017)

Some companies that are related to Teligent include Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Aceto Corporation (ACET), Tetraphase Pharmaceuticals (TTPH), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Marinus Pharmaceuticals (MRNS), BioDelivery Sciences International (BDSI), Aralez Pharmaceuticals (ARLZ), Female Health Company (The) (VERU), Diurnal Group PLC (DNL), BioLife Solutions (BLFS) and Concordia International Corp. (CXRX).

Teligent's management team includes the folowing people:

• Jason Grenfell-Gardner, President, Chief Executive Officer, Director
• Jenniffer L. Collins, Chief Financial Officer
• Stephen Richardson, Chief Scientific Officer
• Carole S. Ben-Maimon M.D., Director
• John E. Celentano, Director
• Steven Hubrig Koehler, Director
• Narendra N. Borkar, Independent Director
• Bhaskar Michael Chaudhuri Ph.D., Independent Director

Teligent's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (10.53%), Pembroke Management LTD (4.25%), Vanguard Group Inc. (3.85%), Elk Creek Partners LLC (3.18%), Broadfin Capital LLC (2.75%) and AMI Asset Management Corp (2.66%). Company insiders that own Teligent stock include James C Gale and Jason Grenfell-Gardner. View Institutional Ownership Trends for Teligent.

Teligent's stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Elk Creek Partners LLC, Broadfin Capital LLC, Pembroke Management LTD, Summit Creek Advisors LLC, Suffolk Capital Management LLC, Kopp Investment Advisors LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Teligent.

Teligent's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Stifel Financial Corp, FMR LLC, Russell Investments Group Ltd., RK Capital Management LLC, Argent Capital Management LLC, Timpani Capital Management LLC and State Street Corp. Company insiders that have bought Teligent stock in the last two years include James C Gale and Jason Grenfell-Gardner. View Insider Buying and Selling for Teligent.

Shares of Teligent can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Teligent stock can currently be purchased for approximately $6.86.